TY - JOUR
T1 - Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer
AU - Gotlieb, Walter H.
AU - Beiner, Mario E.
AU - Shalmon, Bruria
AU - Korach, Yaacov
AU - Segal, Yaacov
AU - Zmira, Nissim
AU - Koupolovic, Joure
AU - Ben-Baruch, Gilad
PY - 2003/10/1
Y1 - 2003/10/1
N2 - OBJECTIVE: To evaluate the safety of fertility-sparing hormonal therapy for endometrial cancer in young patients. METHODS: We reviewed the clinical and pathologic records of patients diagnosed with endometrial adenocarcinoma before the age of 40, who were treated and followed over a 30-year period in the Division of Gynecologic Oncology. All patients who underwent conservative management with progestins (n = 13) are the subjects of this study. RESULTS: Follow-up was available for all 13 patients, with a mean follow-up of 82 months. All patients responded to treatment within a mean period of 3.5 months, with normal pathology on follow-up endometrial samplings. Six patients had a recurrence within a period extending between 19 and 358 months (median 40 months). Four patients were treated with a second course of progestins, and all had a histologic complete response. As of the time of preparation of this report, nine healthy infants had been born, and all the patients remained without evidence of disease. CONCLUSION: Conservative management of well-differentiated endometrial carcinoma in young patients, combined with assisted reproductive technologies, if needed, does not seem to worsen the prognosis. This approach also provides the possibility of conceiving and carrying a normal pregnancy.
AB - OBJECTIVE: To evaluate the safety of fertility-sparing hormonal therapy for endometrial cancer in young patients. METHODS: We reviewed the clinical and pathologic records of patients diagnosed with endometrial adenocarcinoma before the age of 40, who were treated and followed over a 30-year period in the Division of Gynecologic Oncology. All patients who underwent conservative management with progestins (n = 13) are the subjects of this study. RESULTS: Follow-up was available for all 13 patients, with a mean follow-up of 82 months. All patients responded to treatment within a mean period of 3.5 months, with normal pathology on follow-up endometrial samplings. Six patients had a recurrence within a period extending between 19 and 358 months (median 40 months). Four patients were treated with a second course of progestins, and all had a histologic complete response. As of the time of preparation of this report, nine healthy infants had been born, and all the patients remained without evidence of disease. CONCLUSION: Conservative management of well-differentiated endometrial carcinoma in young patients, combined with assisted reproductive technologies, if needed, does not seem to worsen the prognosis. This approach also provides the possibility of conceiving and carrying a normal pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=0141768451&partnerID=8YFLogxK
U2 - 10.1016/S0029-7844(03)00667-7
DO - 10.1016/S0029-7844(03)00667-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0141768451
SN - 0029-7844
VL - 102
SP - 718
EP - 725
JO - Obstetrics and Gynecology
JF - Obstetrics and Gynecology
IS - 4
ER -
